Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

6262 ARTÍCULOS , VIENDO DEL 2821 AL 2835

Dopaminergic Cell Replacement for Parkinson's Disease: Addressing the Intracranial Delivery Hurdle

Maheshwari S, Akram H, Bulstrode H, Kalia SK, Morizane A, Takahashi J, Natalwala A.

J Parkinsons Dis. 2024;14(3):415-435. doi: 10.3233/JPD-230328.

Midbrain organoids for Parkinson's disease (PD) - A powerful tool to understand the disease pathogenesis

Babu HWS, Kumar SM, Kaur H, Iyer M, Vellingiri B.

Life Sci. 2024 May 15;345:122610. doi: 10.1016/j.lfs.2024.122610. Epub 2024 Apr 3.

Indoleamine 2,3-dioxygenase (IDO1) - Can dendritic cells and monocytes expressing this moonlight enzyme change the phase of Parkinson's Disease?

Gonçalves M, Rodrigues-Santos P, Januário C, Cosentino M, Pereira FC.

Int Immunopharmacol. 2024 May 30;133:112062. doi: 10.1016/j.intimp.2024.112062. Epub 2024 Apr 22.

Physical Exercise-Induced Activation of NRF2 and BDNF as a Promising Strategy for Ferroptosis Regulation in Parkinson's Disease

Thirupathi A, Marqueze LF, Outeiro TF, Radak Z, Pinho RA.

Neurochem Res. 2024 Jul;49(7):1643-1654. doi: 10.1007/s11064-024-04152-6. Epub 2024 May 24.

Empowering the management of early-onset Parkinson's disease: The role of technology

Bhidayasiri R, Udomsirithamrong O, de Leon A, Maetzler W, Pilotto A.

Parkinsonism Relat Disord. 2024 Dec;129:107052. doi: 10.1016/j.parkreldis.2024.107052. Epub 2024 Jul 6.

Lower-Limb Exoskeletons for Gait Training in Parkinson's Disease: The State of the Art and Future Perspectives

Fortunati M, Febbi M, Negro M, Gennaro F, D'Antona G, Crisafulli O.

Healthcare (Basel). 2024 Aug 16;12(16):1636. doi: 10.3390/healthcare12161636.

Dyspnea in Parkinson's disease

Jain S, Patel S, Nugent K.

Respir Med. 2024 Nov-Dec;234:107801. doi: 10.1016/j.rmed.2024.107801. Epub 2024 Sep 7.

CBD's potential impact on Parkinson's disease: An updated overview

Hafida EG, Rachid S, Halima G, Najib K.

Open Med (Wars). 2024 Oct 28;19(1):20241075. doi: 10.1515/med-2024-1075. eCollection 2024.

Advantages and Challenges of Platform Trials for Disease Modifying Therapies in Parkinson's Disease

Fabbri M, Rascol O, Foltynie T, Carroll C, Postuma RB, Porcher R, Corvol JC.

Mov Disord. 2024 Sep;39(9):1468-1477. doi: 10.1002/mds.29899. Epub 2024 Jun 26.

Small Molecules in Parkinson's Disease Therapy: From Dopamine Pathways to New Emerging Targets

Lee H, Elkamhawy A, Rakhalskaya P, Lu Q, Nada H, Quan G, Lee K.

Pharmaceuticals (Basel). 2024 Dec 14;17(12):1688. doi: 10.3390/ph17121688.

Physiological effects of dual target DBS in an individual with Parkinson's disease and a sensing-enabled pulse generator

Cummins DD, Sandoval-Pistorius SS, Cernera S, Fernandez-Gajardo R, Hammer LH, Starr PA.

Parkinsonism Relat Disord. 2024 May;122:106089. doi: 10.1016/j.parkreldis.2024.106089. Epub 2024 Mar 6.

Pain and the Non-Pharmacological Management of Pain in People with Parkinson's Disease

Allen NE, Romaliiska O, Naisby J.

J Parkinsons Dis. 2024;14(s1):S65-S80. doi: 10.3233/JPD-230227.

Microbiome-based therapies for Parkinson's disease

Alam M, Abbas K, Mustafa M, Usmani N, Habib S.

Front Nutr. 2024 Nov 6;11:1496616. doi: 10.3389/fnut.2024.1496616. eCollection 2024.

The Zebrafish Model as a New Discovery Path for Medicinal Plants in the Treatment of Parkinson's Disease

Chahardehi AM, Hosseini Y, Mahdavi SM, Naseh I.

CNS Neurol Disord Drug Targets. 2024;23(3):306-314. doi: 10.2174/1871527322666230330111712.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias